Broad Pipeline of Differentiated
Product Candidates
to Fight Cancer & Autoimmune Disorders
Enrolling HER2+ Patients with
Metastatic Breast Cancer
in Phase 3 SOPHIA Study
Leading Multispecific Antibody
Technology Platforms
and Protein Engineering Expertise
Breakthrough Biologics,
Life-Changing
Medicines
Fully-integrated, Antibody-based
Development Capabilities,
Including GMP Manufacturing
Focused on Developing
Innovative Medicines
for Patients with Unmet Needs
Breakthrough Biologics,
Life-Changing
Medicines
Overview

We are a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, autoimmune disorders and infectious diseases.

Corporate Fact Sheet

We’re Hiring!

Our success depends on the talent and dedication of the staff we hire. We are continually expanding our network of individuals who are excited about making a difference in the lives of patients.

Latest News

MacroGenics Announces Date of Second Quarter 2016 Financial Results Conference Call
Read More

MacroGenics Announces Closing of Collaboration and License Agreement with Janssen to Develop MGD015
Read More

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close